CTLA4 and non-small cell lung carcinoma: For example, the latest study suggested that a combination of anti-CTLA4 and anti-PD1 against metastatic melanoma and non-small-cell lung carcinoma (NSCLC) increased the patient’s life expectancy and inhibited metastasis [15,16].